Hints and tips:
...Powell said investors worried that Pfizer had paid a lot for what it had bought....
...Additional reporting by Hannah Kuchler in London...
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Pfizer will not take the twice-daily formulation into late-stage trials but will focus on developing a pill to be taken once a day....
...BioNTech has written down about €900mn on its Covid-19 vaccines because of lower than expected demand for the shots it developed with partner Pfizer....
...Pfizer will keep the commercialisation rights outside the US and Japan. Roivant owns 75 per cent of Telavant, while Pfizer owns 25 per cent....
...The deal is Pfizer’s largest since its 2016 purchase of Medivation for $14.3bn....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Shares in Pfizer added about 1 per cent on Friday, while Seagen was up about 0.9 per cent....
...Pfizer on Tuesday raised $31bn in a jumbo-sized bond sale that will help fund the takeover....
...US pharmaceutical company Pfizer sold the shots, developed with Germany’s BioNTech, for about $19 a dose under the contract signed in 2021, but the new price has not been disclosed....
...Pfizer believes that in 2030 Seagen could contribute more than $10bn in risk-adjusted revenues....
...Shares in oncology-focused biotech Seagen, which Pfizer has agreed to buy for $43bn, also fell amid fears the agency could target other deals in the sector....
...Eli Lilly, Amgen, Pfizer and Regeneron are among the companies aiming to compete with market leader Novo Nordisk in a category which analysts say is rapidly becoming a healthcare priority and could produce...
...Additional reporting by Hannah Kuchler...
...The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim....
...Johnson & Johnson announced in November it had struck a deal to acquire cardiovascular technology group Abiomed for $16.6bn, while Pfizer said in May it had agreed to buy US biotech Biohaven Pharmaceuticals...
...The Federal Reserve is set to raise interest rates by 0.75 points for the fourth time in a row, and Pfizer raised its sales forecast for its Covid-19 vaccine by $2bn to $34bn on Tuesday....
...Pfizer said rebound is “uncommon” and also occurred in the placebo arm of its trial, suggesting it happens to some patients regardless of whether they take the drug....
...Pfizer said the 60 microgram dose produced an immune response that was three times higher than the existing BioNTech/Pfizer vaccine....
...Early use of [Pfizer’s drug] Paxlovid in this case provides additional protection against severe disease.”...
...Haleon was created with consumer health assets from GSK, Pfizer and Novartis....
...Pfizer and EY did not respond to a request for comment....
...Pfizer said 1,678 children had received a third dose of its vaccine in the late-stage clinical trial....
...Email me your thoughts at sid.v@ft.com. Latest news Amy Kazmin in Rome has a fascinating piece on why Giorgia Meloni is pushing back on Italy’s shift to digital payments....
International Edition